This recent study indicates that in a well-designed study of a sample representative of the New Zealand population many people still become sunburned despite a high level of sun protection knowledge.
According to this recent study, every Euro spent by the Danish Sun Safety Campaign saved the Danish health budget €2.18 in health expenses.
This study analysed the prevalence of sun protection behaviour and sunburn incidence of residents of Melbourne, Australia across three decades. The study found the likelihood of people using one or more sun protection behaviours on summer weekends was three times higher in the 1990's than before the programme began, that these improvements were sustained into the 2000's and continued to increase in the 2010's. The study demonstrates the definitive impact of a long standing sun protection intervention, with the authors concluding that the findings are consistent with SunSmart having contributed to a reduction in melanoma among younger people.
According to this recent study, patients with rare BRAF mutations can respond to targeted therapy however efficacy seems to be lower compared with V600E mutated melanoma. Combination BRAFi/MEKi seems to be the best regimen for both V600 and non-V600 mutations.
This recent study suggests skin cancer prevention videos which focus on a single sun protection behaviour are more effective at changing sun protection beliefs and intention than multi-behaviour messages.
PHARMAC is proposing to make changes to the funding criteria for pembrolizumab and nivolumab for advanced melanoma. They are seeking feedback on the proposed criteria by 4 pm Wednesday 6 November 2019.
Conducted by Adjunct Associate Professor Amanda Oakley, this one-day course will address clinical and dermatoscopic diagnosis of common benign and malignant skin lesions, particularly pigmented lesions. All health professionals who undertake skin examinations are invited to attend, whether new to or experienced in dermatoscopy.
PHARMAC are progressing amendment to the Special Authority criteria for both pembrolizumab and nivolumab for advanced melanoma to allow patients who have stopped treatment for reasons other than disease progression or toxicity to recommence funded treatment upon signs of disease progression.
The Health Promotion Agency (HPA) has recently developed a new suite of resources for outdoor workers. These resources ‘bust’ commons myths regarding the sun and support employees and outdoor workers to be SunSmart this summer.
This recent study reported outcomes for real-world patients with advanced melanoma who had elected to discontinue anti-PD-1 therapy with pembrolizumab or nivolumab in the absence of disease progression or treatment-limiting toxicity. Results showed after a median of 18 months after treatment cessation, 78% of patients remained progression-free, and the median time to progression for those who progressed was 12 months.